Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene-3 blocking antibody.
